Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Retrieved on:
Thursday, September 7, 2023
Biologics license application, Partnership, GMT Games, Lyme disease, Senior, DSMB, Saint-Herblain, Vaccination, European Medicines Agency data breach, Valneva SE, PFE, Immunity, Pfizer, Marketing, Șaeș, Data monitoring committee, EMA, Euronext Paris, VLA, Adolescence, European Medicines Agency, Security agency, MAA, Marketing Authorisation Application, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, BLA, NYSE, Food, Vaccine
Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.
Key Points:
- Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.
- Lyme disease continues to spread, representing an important unmet medical need that impacts the lives of many people in the Northern Hemisphere.
- With each new set of positive data, we come one step closer to potentially bringing this vaccine to both adults and children living in areas where Lyme disease is endemic.”
The Phase 2 booster results emphasize the vaccine candidate’s potential to provide immunity against Lyme disease in pediatric and adolescent populations. - “Protection against Lyme disease is important for anyone who lives or spends time outdoors in areas where Lyme disease is endemic.